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ABSTRACT
Cohesin is a multi-protein complex that tethers sister chromatids during mitosis 
and mediates DNA repair, genome compartmentalisation and regulation of gene 
expression. Cohesin subunits frequently acquire cancer loss-of-function alterations 
and act as tumour suppressors in several tumour types. This has led to increased 
interest in cohesin as potential target in anti-cancer therapy. Here we show that the 
loss-of-function of STAG2, a core component of cohesin and an emerging tumour 
suppressor, leads to synthetic dependency of mutated cancer cells on its paralog 
STAG1. STAG1 and STAG2 share high sequence identity, encode mutually exclusive 
cohesin subunits and retain partially overlapping functions. We inhibited STAG1 
and STAG2 in several cancer cell lines where the two genes have variable mutation 
and copy number status. In all cases, we observed that the simultaneous blocking 
of STAG1 and STAG2 significantly reduces cell proliferation. We further confirmed 
the synthetic lethal interaction developing a vector-free CRISPR system to induce 
STAG1/STAG2 double gene knockout. We provide strong evidence that STAG1 is a 
promising therapeutic target in cancers with inactivating alterations of STAG2.
INTRODUCTION
Cohesin is an evolutionarily conserved complex 
composed of four core proteins (SMC1A, SMC3, RAD21 
and either STAG2 or STAG1) that form a ring-shaped 
structure able to encircle chromatin [1]. In somatic cells, 
cohesin is responsible for the cohesion of sister chromatids 
and proper chromosome segregation during mitosis [1, 
2]. Besides this canonical role, cohesin is involved in a 
plethora of other functions including DNA replication 
and repair, regulation of gene expression and genome 
compartmentalisation [3, 4]. All cohesin components, except 
STAG1, have tumour suppressor roles in several cancer 
types, including leukaemia, sarcoma, glioblastoma and 
bladder cancer [5]. The mechanism by which altered cohesin 
contributes to cancer is still unclear. It has been proposed 
that defects in chromatid cohesion may be responsible for 
cancer aneuploidy and increased genomic instability [3, 6]. 
However, several cancers with inactivating alterations in 
the cohesin complex maintain a nearly normal karyotype. 
This led to speculation that the alteration of other cohesin 
functions, such as transcriptional deregulation or defective 
DNA repair, may contribute to cancer [7, 8].
Given their widespread tumour suppressor activity, 
cohesin proteins are of obvious clinical interest for the 
development of targeted cancer therapy. However, tumour 
suppressors are difficult to target directly because they 
require agonists or activators that are able to rescue the 
lost functions. An alternative strategy is to target tumour 
suppressors indirectly by interfering with their synthetic 
lethal partners. Synthetic lethality indicates a genetic 
interaction where the concomitant alteration of two 
nonessential genes leads to cell death while the alteration of 
either gene individually is viable. Blocking synthetic lethal 
partners of tumour suppressor genes is a powerful way to 
selectively kill cancer cells where they are inactive, while 
the normal cells remain viable because the genes are wild-
type (WT) [9]. Synthetic lethality is the outcome of different 
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types of genetic interactions that make the cell resilient 
to single gene loss, including back up pathways, rewired 
intracellular networks or functional compensation due to 
genetic redundancy. Genes that originate via duplication 
(paralogs) are interesting candidates for functional 
compensation because paralogs often preserve some degree 
of redundancy. Therefore, the identification of ‘paralog 
dependencies’ is an emerging strategy to uncover cancer 
vulnerabilities of potential relevance in cancer therapy [10].
Here we investigate whether paralog dependency is 
established in cancers that acquire loss-of-function (LoF) 
alterations in the cohesin complex. We focus specifically 
on STAG1 and STAG2 because they are duplicated cohesin 
subunits that are both expressed in somatic cells. Using 
a variety of experimental approaches and cell lines, we 
show that STAG1 and STAG2 are synthetic lethal partners 
and provide evidence that STAG1 is a potential therapeutic 
target in tumours where STAG2 is inactive.
RESULTS
Evidence of functional compensation between 
STAG1 and STAG2
STAG1 and STAG2 encode two proteins with 70% 
amino acid identity and the same domain organisation 
(Figure 1A). These proteins are mutually exclusive subunits 
of two distinct cohesin complexes – cohesin SA1 and cohesin 
SA2 – that have undergone partial subfunctionalization while 
still preserving overlapping functions [3] (Figure 1B). For 
example, both complexes mediate chromatid cohesion along 
chromosome arms [11, 12], while cohesin SA1 and cohesin 
SA2 tether telomeric and centromeric sister chromatids, 
respectively [11]. Additionally, the two complexes play both 
overlapping and distinct roles in gene expression regulation 
[12] and in DNA damage checkpoint in response and 
repair [13]. Interestingly, the depletion of STAG1 in HeLa 
cells results in increased STAG2 expression and vice versa, 
thus suggesting some degree of compensation between the 
two genes [13]. However, so far the functional interaction 
between these two genes has not been investigated in detail.
Both STAG1 and STAG2 acquire somatic LoF 
alterations (homozygous gene deletions, truncating 
mutations and multiple hits; see Methods) as well as putative 
damaging missense and splicing mutations in a variety of 
human cancers of The Cancer Genome Atlas (TCGA, Figure 
1C). However STAG2, but not STAG1, has been identified 
as a tumour suppressor in leukaemia, sarcoma, glioblastoma 
and bladder cancer [14–20] (Table 1). This may be due to 
the localisation of STAG2 on the X chromosome that makes 
a single hit sufficient to inactivate the gene. LoF alterations 
are clearly associated with a significant reduction of STAG2 
expression in cancer cell lines and in TCGA samples (Figure 
1D), supporting a reduced gene activity after somatic 
inactivation. Also, STAG1 expression slightly increases 
in cell lines with LoF alterations in STAG2, although this 
is not observed in human samples (Figure 1E). Therefore, 
despite the effects of STAG2 depletion on STAG1 expression 
seem context-specific (see also below), in some cases it 
may lead to increased levels of STAG1. This, coupled with 
high sequence identity and partially overlapping functions, 
suggests a functional compensation, and possibly a synthetic 
lethal interaction, between the two genes.
Transient gene knockdown validates synthetic 
lethality between STAG1 and STAG2
To validate the predicted synthetic lethal interaction 
between STAG1 and STAG2, we inactivated them in 
the CAL-51 cancer cell line where both genes are WT 
(Supplementary Table 1). We knocked down each gene 
individually or both simultaneously with gene-specific 
short interfering RNAs (siRNAs), using negative siRNAs 
as a control (Supplementary Table 2). First, we confirmed 
decreased mRNA levels and undetectable protein expression 
of the knocked down genes (Figure 2A). Then we measured 
cell proliferation 24, 48, 72 and 96 hours after transfection. 
To ensure that these measures were comparable across 
replicates and independent of the number of initially 
seeded cells in each condition, we normalised each time 
point to the value measured at 24 hours. We found that 
viable cells after the simultaneous silencing of STAG1 and 
STAG2 were significantly lower than the control (Figure 
2B), supporting synthetic lethality between the two genes. 
Crystal violet staining of CAL-51 cells 120 hours after 
transfection confirmed that the double knockdown (KD) of 
STAG1 and STAG2 led to a drastic reduction in the number 
of cells (Figure 2C). To test whether the observed effect was 
universal or rather specific to CAL-51 cells, we repeated the 
KD experiment in MCF-7 breast cancer cells, another cell 
line in which both genes are WT (Supplementary Table 1). 
Interestingly, STAG2 expression in MCF-7 cells increased 
when STAG1 was knocked down (Figure 2D), in agreement 
with what has been previously reported in HeLa cells [13]. 
However, the same signal was not observed in CAL-51 
cells (Figure 2A), suggesting that the changes in the relative 
expression of the two genes are context-specific. We then 
monitored the effect of the individual or simultaneous 
blocking of STAG1 and STAG2 on MCF-7 cell proliferation 
as compared to the control. As we found for CAL-51, the 
proliferation of MCF-7 was significantly impaired in the 
presence of the double KD of STAG1 and STAG2 (Figure 
2E). Finally, we tested whether the inhibition of STAG1 
alone was enough to reduce cell proliferation when STAG2 
was already inactive. This condition mimics that of cancer 
samples where STAG2 is somatically inactivated and 
supports the development of STAG1 as a therapeutic target 
in these tumours. To test this, we used SK-ES-1, a sarcoma 
cell line with a somatic homozygous point mutation in 
STAG2 (Supplementary Table 1). This mutation introduces 
a premature stop codon (Figure 2F) resulting in the 
abolishment of the full-length STAG2 protein expression 
(Figure 2G). We knocked down STAG1 via siRNA (Figure 
2H) and monitored its effect on cell growth. However, 
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Figure 1: Evidence of functional compensation between STAG1 and STAG2. Legend: (A) Sequence identity and domain 
architecture of STAG1 and STAG2 proteins as annotated in the SMART database [57]. (B) Composition and biological functions of cohesin 
SA1 and cohesin SA2. (C) Fraction of TCGA cancers with LoF alterations (homozygous gene deletions, truncating mutations and multiple 
hits) or damaging missense and splicing mutations in STAG1 or STAG2 divided by tumour type. The total number of sequenced samples 
in TCGA is reported in brackets. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous 
cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; ESCA, oesophageal carcinoma; GBM, glioblastoma 
multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary 
cell carcinoma; LAML, acute myeloid leukaemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung 
adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; 
PCPG, pheochromocytoma and paraganglioma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; 
TGCT, testicular germ cell tumours; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. (D) Expression profiles of 
STAG2 when it acquires damaging or LoF alterations as compared to when it is WT in cancer cell lines from the Cell Line Project (CLP, 
http://cancer.sanger.ac.uk/cell_lines) and in TCGA samples and. (E) Expression profiles of STAG1 when STAG2 acquires damaging or LoF 
alterations as compared to when it is WT in CLP cell lines and in TCGA samples. The numbers of mutated samples or cell lines are reported 
in brackets. Distributions were compared using the Wilcoxon test and corresponding p-values are shown; ns = not significant.
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the measure of SK-ES-1 cell proliferation via enzymatic 
activity yielded inconsistent results even for untreated cells 
(Supplementary Figure 1A). This is likely because SK-
ES-1 cells tend to form aggregates (Supplementary Figure 
1B) that prevent uniform incorporation of the reagents 
needed for the assay. Therefore, instead of measuring cell 
proliferation, we counted the number of SK-ES-1 cells 96 
hours after transfection with negative siRNAs or STAG1 
siRNA. Each transfection was repeated six times and cells 
were counted blindly and independently by two operators. 
We found that the number of cells after of STAG1 KD was 
significantly lower than the control (Figure 2I). Although 
we did not detect any full-length protein (Figure 2G), 
STAG2 mRNA is still expressed in SK-ES-cells according 
to the gene expression profile of the cancer cell line project 
[21]. To rule out the possibility that a truncated version 
of STAG2 protein was still functional, we knocked down 
both genes. We confirmed that the simultaneous KD of 
STAG1 and STAG2 had no further detrimental effect on the 
proliferation of SK-ES-1 cells (Figure 2I). Therefore, the 
blocking of STAG1 alone is sufficient to impair cell growth 
when STAG2 is inactive.
Stable gene knockout of STAG1 and STAG2 
confirms synthetic lethality
Next, we tested whether the synthetic lethal 
interaction between STAG1 and STAG2 could be confirmed 
through stable knockout (KO) of STAG1 or STAG2 in 
addition to transient KD of the respective paralog. To stably 
inactivate STAG2, we developed a vector-free (vf) CRISPR 
system (Figure 3A). First, we induced Cas9 expression in 
CAL-51 cells (Figure 3B). We then transfected CAL-51 
Cas9 expressing cells with a universal trans-activating 
RNA (tracrRNA) and three different STAG2-specific 
CRISPR targeting RNAs (crRNAs, Supplementary 
Table 2). We selected the optimal STAG2 crRNA based 
on editing efficiency (Figure 3C) and used it in further 
experiments. Starting from a heterogeneous population 
of STAG2-edited cells, we performed single cell cloning 
and identified a clone with homozygous STAG2 editing 
using the High Resolution Melting assay (Figure 3D). 
Sequencing of the edited region confirmed a homozygous 
eight-nucleotide-long deletion producing a frameshift in 
the STAG2 protein after Leucine 161 (L161fs-STAG2, 
Figure 3E). We detected no STAG2 mRNA (Figure 3F) or 
protein (Figure 3G) expression in CAL-51 L161fs-STAG2 
cells. To test the synthetic lethal interaction between 
STAG1 and STAG2 in the presence of stably inactivated 
STAG2, we transfected CAL-51 L161fs-STAG2 cells with 
either STAG1 siRNA or negative siRNA. We found that cell 
proliferation 96 hours after transfection with STAG1 siRNA 
was significantly lower than the control (Figure 3H).
To stably inactivate STAG1, we infected CAL-
51 cells with a lentiviral vector containing Cas9sp, an 
antibiotic resistance marker, and a STAG1 guide RNA 
(gRNA, Figure 4A, Supplementary Table 2). After 
antibiotic selection, we obtained STAG1 CAL-51 edited 
cells (CAL-51 crVector-STAG1, Figure 4B). Although 
STAG1 mRNA level in CAL-51 crVector-STAG1 cells was 
comparable to the control (Figure 4C), no STAG1 protein 
was detected (Figure 4D). We then transfected CAL-51 
crVector-STAG1 cells directly with either STAG2 siRNA 
or negative siRNA. Again, we found that the silencing of 
STAG2 significantly reduced the proliferation of crVector-
STAG1 cells as compared to the control (Figure 4E). 
Using a similar approach, we generated stable STAG1 KO 
in sarcoma (U2OS), uterine carcinoma (MFE-319) and 
bladder carcinoma (RT-112) cell lines that have both genes 
WT, but with a different number of copies (Supplementary 
Table 1). We first induced STAG1 editing (Figure 4F) and 
then transfected the cells with STAG2 or control siRNAs, 
observing significant reduction of cell proliferation only 
when both genes were blocked (Figure 4G).
Table 1: Cancer driver role and paralogy relationship of human cohesin subunits
Cohesin subunit Cancer type Reference(s) Paralog(s)




Acute myeloid leukaemia [7, 59]





Acute myeloid and lymphoblastic leukaemia [7, 59, 61, 62]
Paediatric and adult Ewing sarcoma [18, 19, 63]
Glioblastoma [20]
Reported are the cancer types and associated studies where somatic modifications of the cohesin subunit are cancer drivers. 
* = active in meiosis.
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As a final validation, we measured the effect of the 
stable KO of both STAG1 and STAG2 in two different 
experimental settings. In the first experimental setting, 
we compared the growth of CAL-51 L161fs-STAG2 cells 
and CAL-51 Cas9 cells after infection with the STAG1 
Cas9 lentiviral vector (Figure 5A). Crystal violet staining 
showed that while STAG1 edited cells reached around 
75% confluence after ten days of antibiotic selection, the 
double editing of both genes critically reduced the number 
of cells (Figure 5B). In the second experimental setting, 
Figure 2: Effect of transient blocking of STAG1 and STAG2 on cell proliferation. Legend: (A) STAG1 and STAG2 gene (left) 
and protein (right) expression in CAL-51 cells 48 hours and 72 hours after siRNA transfection, respectively. (B) Proliferation curve of CAL-
51 cells after transfection with negative, STAG1 and STAG2 siRNAs. Three biological replicates were done and the KD was repeated three 
times in each replicate. (C) Crystal violet staining of CAL-51 cells 120 hours after transfection with negative, STAG1 and STAG2 siRNAs. 
(D) STAG1 and STAG2 expression measured by quantitative RT-PCR in MCF-7 cells 72 hours after siRNA transfection. (E) Proliferation 
curve of MCF-7 cells after transfection with negative, STAG1 and STAG2 siRNAs. Two biological replicates were done and the KD was 
repeated three times in each replicate. (F) Sanger sequencing confirmation of STAG2 homozygous nonsense mutation in SK-ES-1 cells. (G) 
Immunoblots of STAG1 and STAG2 protein expression in untreated SK-ES-1 cells. (H) STAG1 mRNA expression in SK-ES-1 cells after 
siRNA transfection as compared to the control. (I) Number of SK-ES-1 cells 96 hours after transfection of STAG1 or STAG1 and STAG2 
siRNAs as compared to the control. Each KD was repeated six times and cells were counted blindly and independently. Average number of 
cells and associated standard errors across replicates for each condition are shown. Means were compared using one-tailed Student’s t-test. 
In all quantitative RT-PCR experiments, β-2-microglobulin was used for normalisation. Shown are mean and standard error of normalized 
expression values across replicates. In all proliferation curves, Relative Fluorescent Unit (RFU) values were normalised to the mean across 
replicates at 24 hours. Mean values at 96 hours were compared using the one-tailed Student’s t-test; ns = not significant.
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we used the vf-CRISPR system to edit STAG1 in both 
CAL-51 L161fs-STAG2 cells and CAL-51 Cas9 cells 
(Figure 5C). Here the expectation was that because of 
synthetic lethality, STAG1 editing should be significantly 
less efficient in CAL-51 L161fs-STAG2 cells as compared 
to CAL-51 Cas9 cells. As we did for STAG2, we tested 
three different STAG1 crRNAs and used the one with the 
highest editing efficiency (Supplementary Figure 2A). 
Moreover, we added Cas9 protein to the transfection 
mix after verifying that this further improves the editing 
efficiency (Supplementary Figure 2B). As a further control 
to rule out the possibility that STAG2 KO would interfere 
with any additional gene editing, we edited EMX1, an 
unrelated gene that is broadly used as a positive control for 
CRISPR-induced gene editing [22, 23], in both cell lines 
under the same conditions used to edit STAG1 (Figure 5C). 
While we observed comparable EMX1 editing efficiency in 
CAL-51 L161fs-STAG2 cells and in CAL-51 Cas9 cells, 
STAG1 editing was clearly detectable in CAL-51 Cas9 
cells but almost absent in CAL-51 L161fs-STAG2 cells 
(Figure 5D). Quantification of the gel bands corresponding 
to the edited regions confirmed no difference in the 
Figure 3: Synthetic lethality between STAG1 and STAG2 in stably edited STAG2 cells. Legend: (A) Schematic diagram to 
derive STAG2 KO clones via vector-free (vf) CRISPR editing. CAL-51 cells are first infected with a Cas9 containing lentiviral vector to 
induce Cas9 expression and then transfected with a universal trans-activating RNA (tracrRNA) and gene-specific CRISPR targeting RNAs 
(crRNAs). Finally, edited clones are isolated via single cell cloning. (B) Evidence of Cas9 mRNA expression in CAL-51 Cas9 cells. (C) 
T7 endonuclease 1 assay (T7E1) assay on the edited regions of STAG2 after transfection with three STAG2-crRNAs. STAG2b (red box) 
was selected because of its higher editing efficiency. (D) High Resolution Melting Assay on isolated clones after single cell cloning from 
a heterogeneous population of STAG2 edited cells. The assay was used to identify clones with homozygous STAG2 editing. (E) Sanger 
sequencing confirmation of the eight-base-pair-long homozygous deletion in CAL-51 L161fs-STAG2 cells. (F) Expression of STAG2 via 
quantitative RT-PCR in CAL-51 L161fs-STAG2 cells and in CAL-51 Cas9 cells. β-2-microglobulin was used for normalisation. Shown 
are mean and standard error of normalized expression values across replicates. (G) Western blots of STAG2 protein expression in CAL-51 
L161fs-STAG2 cells and CAL-51 Cas9 cells. (H) Proliferation curve of CAL-51 L161fs-STAG2 cells after transfection with negative or 
STAG1 siRNAs. Three biological replicates were done and the KD was repeated three times in each replicate. Relative Fluorescent Unit 
(RFU) values were normalised to the mean across replicates at 24 hours. Mean values at 96 hours were compared using the one-tailed 
Student’s t-test.
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fraction of EMX1 editing and a significantly lower 
fraction of STAG1 editing in CAL-51 L161fs-STAG2 
cells as compared to CAL-51 Cas9 cells (Figure 5E). This 
excludes the possibility that CAL-51 L161fs-STAG2 cells 
are resistant to additional gene editing and proves specific 
counter selection of STAG1 and STAG2 simultaneous KO 
due to the synthetic lethality between the two genes.
DISCUSSION
The cohesin complex has recently attracted increased 
attention as an interesting therapeutic target because of 
its frequent somatic inactivation in cancer. For example, 
it has been shown that, STAG2-deficient glioblastoma 
cells, although not STAG2-deficient Ewing sarcoma cells 
[24], are more responsive than STAG2 proficient cells to 
treatment with PARP inhibitors [25]. Synthetic lethality 
between cohesin and PARP has been explained by their 
respective roles in recovering and maintaining the integrity 
of stalled replication forks [26]. In the presence of defective 
cohesin, cancer cells become dependent on replication fork 
mediators, such as PARP, to replicate the genome correctly 
and efficiently [27]. When these mediators are also inhibited, 
the replication fork cannot progress resulting in double 
strand breaks [26]. This is an example of synthetic lethality 
resulting from the concomitant inhibition of two independent 
pathways that are nonessential per se but that both contribute 
to an essential process – in this case DNA replication. Cells 
with altered cohesin are also sensitive to the inhibition of the 
anaphase promoting complex/cyclosome (APC/C), which 
is required for exiting mitosis after proper chromosome 
segregation [28]. In this case, synthetic lethality between 
Figure 4: Synthetic lethality between STAG1 and STAG2 in stably edited STAG1 cells. Legend: (A) Schematic representation 
of vector-mediated STAG1 editing. Cells were infected (CAL-51) or transfected (U2OS, MEF-319, RT-112) with a STAG1-Cas9 vector. 
Resulting STAG1 edited cells were subsequently isolated (see Methods). (B) T7E1 assay on STAG1 edited region in crVector-STAG1 
CAL-51 cells. (C) STAG1 expression in CAL-51 Cas9 and crVector-STAG1 cells. β-2-microglobulin was used for normalisation. Shown 
are mean and standard error of normalized expression values across replicates. (D) Western blots of STAG1 in CAL-51 Cas9 cells and 
crVector-STAG1 cells. (E) Proliferation curve of CAL-51-Cas9 and crVector-STAG1 cells after transfection with negative or STAG2 
siRNAs. (F) T7E1 assay on STAG1 edited region in crVector-STAG1 U2OS, MFE-319, and RT-112 cells, respectively. (G) Proliferation 
curve of U2OS, MFE-319, and RT-112-Cas9 and corresponding crVector-STAG1 cells after transfection with negative or STAG2 siRNAs. 
All proliferation assays were done in triplicates, except for MFE-319 where two replicates were performed, and the KD was repeated three 
times in each replicate. Relative Fluorescent Unit (RFU) values or Optical Density at 570 nm (OD-570) values were normalised to the 
mean across replicates at 24 hours and log2 transformed. Mean values at 96 hours were compared using the one-tailed Student’s t-test; ns 
= not significant.
Oncotarget37626www.impactjournals.com/oncotarget
cohesin and APC/C derives from the additive effect of their 
simultaneous inhibition, namely weak chromatid cohesion 
and delayed exit from mitosis [28].
Here we describe yet another mechanism of 
synthetic lethality involving cohesin that results from 
the ability of two paralogous genes, STAG1 and STAG2, 
to compensate for each other. This is due to the gene 
common evolutionary origin, high sequence conservation 
and partial retention of original functions. In several 
cancer types, the somatic inactivation of STAG2 is 
selected for due to its tumour suppressor role. However, 
this yields mutated cells that become dependent on 
STAG1 and sensitive to its inhibition. Our data on SK-
ES-1 cells, which have inactive STAG2 gene, show that 
this vulnerability can be exploited to specifically target 
STAG2-altered cancers by developing specific STAG1 
inhibitors. Moreover, it has been recently reported that 
STAG2 inactivation confers resistance to BRAF inhibitors 
in melanoma [29]. The vulnerability of STAG2-deficient 
cells towards STAG1 inhibition may help overcome 
the onset of this resistance. Paralog dependencies that 
create cancer vulnerabilities have already been described 
Figure 5: Synthetic lethality between STAG1 and STAG2 via double gene editing. Legend: (A) Schematic representation 
of STAG1 and STAG2 double gene editing using a lentiviral vector. CAL-51 L161fs-STAG2 and CAL-51 Cas9 cellswere infected with 
the STAG1-Cas9 lentiviral vector and subjected to puromycin selection to produce STAG1-STAG2 and STAG1 edited cells, respectively. 
(B) Crystal violet staining of CAL-51 STAG1 and STAG1-STAG2 edited cells ten days after puromycin selection. Less than 150 cells were 
counted in CAL-51 STAG1-STAG2 edited cells as compared to around 200,000 CAL-51 STAG1 edited cells. (C) Schematic representation 
of the STAG1 and STAG2 double gene editing using the vf-CRISPR system. STAG1 or EMX1 were edited using the vf-CRISPR system 
on CAL-51 L161fs-STAG2 and CAL-51 Cas9 cells to generate STAG1-STAG2 or EMX1-STAG2 or STAG1 or EMX1 edited cells, 
respectively. (D) Representative T7E1 assay on EMX1 and STAG1 edited regions in CAL-51 Cas9 and CAL-51 L161fs-STAG2 cells. 
(E) Quantification of EMX1 and STAG1 gene editing in CAL-51 Cas9 and CAL-51 L161fs-STAG2 cells. Each gene editing was repeated 
three times and each time the percentage of editing was quantified using ImageJ. Barplots show the mean percentage of gene editing 
and associated standard errors across replicates. One-tailed Student’s t-test was used to assess statistical significance and corresponding 
p-values are shown; ns = not significant.
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for another chromatin-related complex, the SWI/SNF 
complex. In this case, cancer cells lacking SMARCA4 or 
ARID1A, two core components of the SWI/SNF complex, 
become dependent on the corresponding paralogs, 
SMARCA2 and ARID1B, respectively [30–33]. As a 
result, the SWI/SNF complex has attracted a great deal of 
attention for the development of targeted cancer therapies 
[34, 35]. Our results suggest that paralog dependency is a 
general mechanism to buffer single gene loss. As such, it is 
a powerful strategy to discover cancer vulnerabilities [10].
Synthetic dependencies are often difficult to validate 
experimentally because of their context specificity, 
partial silencing and widespread off-target effects of 
common approaches based on RNA interference [9]. 
To prove that the synthetic lethality between STAG1 
and STAG2 is context independent, we have tested their 
genetic interaction in several cancer cell lines where the 
two genes have variable mutational and copy number 
status. As already reported in the literature [14, 16, 36], 
we confirm that the impairment of either STAG paralog 
alone has a context-specific effect on cell proliferation. In 
our experiments, blocking STAG1 or STAG2 has either no 
effect or can slightly reduce cell proliferation. However, the 
concomitant blockade of both genes leads to substantially 
lower cell growth in all cell lines that we have tested. 
Moreover, we have induced gene inhibition with both RNA 
interference and gene editing, obtaining comparable results 
in all cases. Our vf-CRISPR-based system induces stable 
gene KO through the formation of a transient Cas9-crRNA-
tracrRNA complex. This represents a major advantage 
to reduce off-target effects that are likely to occur when 
all CRISPR-Cas9 components are stably expressed [37]. 
Similar vf-CRISPR approaches have recently been used to 
induce gene editing in vitro [38–40] and in vivo [41–43]. 
In most of these studies, gRNAs are first generated via 
in vitro transcription and then transfected with Cas9 into 
the cells. Alternatively, all CRISPR-Cas9 components are 
injected directly into the cells. Here, we further simplify 
this approach to prove that a simple transfection is able 
to induce editing of single and multiple genes and can be 
efficiently applied to prove genetic interactions.
MATERIALS AND METHODS
STAG1 and STAG2 somatic alterations in TCGA 
and cancer cell line project
Somatic mutations (single nucleotide variants 
and small indels), segmented copy numbers and RNA 
sequencing data were downloaded from TCGA Data 
Matrix portal (Level 3, https://tcga-data.nci.nih.gov/
docs/publications/tcga/) for 31 cancer types. Only non-
hypermutated samples with a number of mutations within 
the third quartile of the distribution of mutations for the 
corresponding cancer type were further retained. STAG1 
and STAG2 were considered as somatically inactive if they 
acquired LoF alterations or damaging alterations. LoF 
alterations were identified as homozygous gene deletions, 
truncating mutations (stopgain, stoploss, frameshift 
indels) or multiple hits (combination of heterozygous 
gene deletions, truncating and damaging mutations). 
Damaging alterations were defined as missense and 
splicing mutations with predicted damaging effects on the 
protein. Missense mutations were considered damaging if 
supported by at least five out of eight function-based scores 
(SIFT [44], PolyPhen-2 HDIV [45], PolyPhen-2 HVAR 
[45], MutationTaster [46], MutationAssessor [47], LTR 
[48] and FATHMM [49]) or two out of three conservation-
based scores (PhyloP [50], GERP++ RS [51], SiPhy 
[52]). Splicing mutations were predicted as damaging if 
supported by at least one ensemble score of dbscSNV 
[53]. STAG1 and STAG2 were considered deleted if their 
copy numbers (CN) were <0.5 (homozygous deletion) or 
<1.5 (heterozygous deletion). CN was measured as
CN xsegment mean= 2 2
where segment mean is the segment copy number of 
STAG1 or STAG2 genomic regions.
To compare the expression of mutated and WT 
STAG1 and STAG2, we converted either the Expectation-
Maximization (RSEM) or the Reads Per Kilobase per 
Million mapped reads (RPKM) into transcripts per million 









RSEM were multiplied by one million to obtain the 
corresponding TPM.
STAG1 and STAG2 somatic mutations and Affymetrix 
U219 expression data in 971 cancer cell lines were obtained 
from the cancer Cell Lines Project (CLP, http://cancer.sanger.
ac.uk/cell_lines). LoF alterations were defined as stopgain, 
stoploss and frameshift indels. Damaging mutations 
were identified from the CLP annotation. The expression 
levels of STAG1 and STAG2 were derived from CLP and 
measured as Z-scores of Robust Multiarray Average (RMA)-
normalised expression values [54].
Cell lines
The cell lines used in this study (CAL-51, MCF-
7, SK-ES-1, U2OS, MFE-319 and RT-112) were all 
validated by short tandem repeat analysis. Cells were 
grown at 37°C and five per cent CO2 in DMEM 10% 
FBS (CAL-51, U2OS), DMEM 10% FBS 0.01 mg/ml 
human recombinant insulin (MCF-7), McCoy’s 20% calf 
serum (SK-ES-1), DMEM-RPMI 20% FBS (MFE-319) 
and RPMI 10% FBS (RT-112). To confirm the STAG2 
mutation in SK-ES-1 cells, genomic DNA was extracted 
using GenElute mammalian genomic DNA miniprep 
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kit (Sigma-Aldrich) according to the manufacturer’s 
protocol. Sanger sequencing was performed after PCR 
amplification of a 634-base-pair-long genomic region 
surrounding the STAG2 mutated position as annotated in 
CLP (Supplementary Table 2).
siRNA transfection
Transfection was performed with lipofectamine 
RNAiMAX (Thermo Fisher Scientific) and mission pre-
designed siRNA oligos specific for STAG1 and STAG2 
(Supplementary Table 2) using two universal negative 
siRNA oligos as controls (Sigma-Aldrich) following 
the manufacturer’s protocol. For proliferation assays, 
transfections were performed in 96-well plates, while for 
RNA and protein extraction, transfections were performed 
in 24-well plates and 6-well plates, respectively. In all 
assays, the total concentration of the RNAi oligos was 
50 nM (25 nM for each siRNA). For the double KD, the 
two STAG1 and STAG2 siRNA oligos were mixed. For 
the single KD, the siRNA specific either for STAG1 or 
STAG2 was combined with one of the universal negative 
siRNA oligos. For the control, the two universal negative 
siRNA oligos were used.
Quantitative RT-PCR
Total RNA was extracted using GenElute 
mammalian total RNA miniprep kit (Sigma-Aldrich). 
Reverse transcription was performed starting from 175 
ng RNA using GoScriptTM reverse transcription system 
(Promega). cDNAs were subjected to quantitative PCR 
using predesigned SYBR green primers (Sigma-Aldrich; 
Supplementary Table 2) and SYBR Green JumpStart 
Taq ReadyMixTM (Sigma-Aldrich). Gene expression 
levels were assessed in triplicate using ViiA7 thermal 
cycler (Applied Biosystems) and the average expression 
level across triplicates (e) was relativized to the average 
expression level of β-2-microglobulin (c):
r e c= -
where r is the relative gene expression.
The fold change (fc) between the relative gene 
expression after KD (rKD) and the relative gene expression 
in the control condition (rc) was calculated as:
fc 2 r rKD c= ( )−
Each experiment was repeated in biological duplicate.
Western blot analysis
CAL-51 cells were seeded at 70% confluence in 60 
mm plates, grown for 48 hours after gene KD or for 24 
hours after CRISPR editing, washed twice with PBS and 
lysed with RIPA buffer. Protein amounts present in the cell 
lysates were measured using Pierce BCA protein assay kit 
(Thermo Fisher Scientific). Five to ten micrograms of 
protein were loaded in TruPAGETM precast gels (Sigma-
Aldrich). STAG1, STAG2 or GAPDH proteins were 
detected by incubating membranes overnight with anti-
STAG1 prestige rabbit antibody at 1/150 dilution (Sigma 
Life Science, HPA035015), anti-STAG2 mouse antibody 
1/500 dilution (Sigma-Aldrich, WHO0010735M1) or anti-
GAPDH mouse antibody 1/10000 dilution (MAB374, 
clone 6C5, EMD Millipore), respectively. After washing 
with 0.01% PBS-Tween 20, membranes were incubated 
with peroxidase-conjugated anti-mouse or anti-rabbit 
antibodies (1:5000, Mouse IgG HRP-linked Whole Ab 
NA934 and Rabbit IgG HRP-linked Whole Ab NA934, 
GE Healthcare) for 45 minutes and washed before 
detection by chemiluminescence (ECL, GE Healthcare).
Proliferation assays and crystal violet staining
Cell proliferation was measured every 24 hours for 
four days, starting one day after transfection using either 
CellTiter-FluorTM cell viability assay (Promega) or crystal 
violet staining followed by dye extraction using methanol 
and optical density measured at 570 nm [55]. Briefly, 5x103 
cells/well transfected with STAG1, STAG2 or negative 
siRNAs were seeded on 96-well plates in a final volume 
of 100 μl per well. For the CellTiter-FluorTM cell viability 
assay (Promega), at each time point, 20 μl of the diluted 
reagent (10 μl of the GF-AFC Substrate in 2 ml of Assay 
Buffer) was added to each well. After one hour and 30 
minutes, fluorescence was measured at 380–400 nmEx/505Em 
using a Fusion alpha-FP (Perkin Elmer). Each condition 
was assessed in triplicate and the whole experiment was 
repeated at least twice. Crystal violet staining was used to 
visualise the effect of STAG1 and STAG2 KD on CAL-51 
cells. Briefly, 70000 cells were seeded on 12-well plates 
and transfected with the universal negative control, STAG1, 
STAG2 or STAG1 and STAG2 siRNAs. After five days, 
cells were fixed with ice-cold 100% methanol and stained 
with 0.1% crystal violet. After 30 minutes, cells were 
washed three times with water and dried.
STAG1 editing with CRISPR vectors and T7E1 
assay
CAL-51 cells were transduced with the lentiviral 
vector (pLV-U6g-EPCG) containing Cas9sp, the 
puromycin resistance marker and a STAG1 gRNA 
(Sigma-Aldrich). The gRNA was composed of a universal 
86-nucleotide-long tracRNA and 20-nucleotide-long 
STAG1-specific crRNA (Supplementary Table 2). Forty-
eight hours after infection, stably transduced cells were 
selected with puromycin (6μg/ml). U2OS, MFE-319 and 
RT-112 cells were transfected with a vector containing 
Cas9sp, the Orange Fluorescent Protein (OFP) reporter 
(GeneArt Nuclease, Thermo Fisher Scientific) and the 
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STAG1 gRNA1a (Supplementary Table 2). Forward and 
reverse strand oligos corresponding to STAG1 gRNA1a 
were synthesized with 3’overhangs nucleotides according 
to the manufacturer’s protocol. Resulting oligos were 
annealed and cloned into the linearized GeneArt Nuclease 
vector. After verification of STAG1 gRNA integration via 
Sanger sequencing, cells were transfected using Fugene6 
(Promega) and OFP positive cells were sorted after 72 
hours. The per cent of edited cells was assessed two weeks 
after selection or one week after OFP positive cell sorting 
using the T7 endonuclease 1 (T7E1) assay (New England 
Biolabs), following the manufacturer’s protocol. Briefly, 
the genomic site targeted by the STAG1 crRNAs was 
amplified from 100 ng of genomic DNA extracted with 
GenElute genomic DNA extraction kit (Sigma-Aldrich), 
using Q5 Hot Start High-Fidelity 2X Master Mix (New 
England Biolabs) and specific primers (Supplementary 
Table 2). Amplicons of 700-800 base pairs were purified 
using GenElute PCR clean-up kit (Sigma-Aldrich) and 200 
ng of PCR products were denatured, annealed and digested 
with the T7 endonuclease 1 enzyme (New England 
Biolabs) for 15 minutes. Digested products were run 
on a two per cent agarose gel and the intensity of bands 
corresponding to the full-length amplicon and, in presence 
of editing, the two digested fragments were quantified with 
ImageJ [56] and GelAnalyzer (http://www.gelanalyzer.
com/index.html). Each band was quantified three times 
and the whole experiment was repeated three times.
Generation of CAL-51-Cas9 expressing cells and 
gene editing with vector-free CRISPR
CAL-51 cells were transduced with a lentiviral 
vector containing Cas9sp (GeCKO-tEf1aCas9Blast, 
Sigma-Aldrich) and blasticidin resistance marker. After 
10 days of treatment with blasticidin (25 ug/ml), resistant 
cells were selected and Cas9sp expression was verified 
via PCR (Supplementary Table 2). STAG1 and STAG2 
crRNAs (Sigma-Aldrich, Supplementary Table 2) were 
co-transfected with 69-mer tracrRNA (Sigma-Aldrich) 
together with GeneArt Platinum Cas9 nuclease (Life 
Technologies) using lipofectamine CRISPRMAX (Life 
Technologies). The per cent of edited cells was assessed 
72 hours after transfection using the T7E1 assay (New 
England Biolabs) as reported above.
Isolation and identification of STAG2 edited 
clones
STAG2 was edited on 200,000 CAL-51 Cas9 
expressing cells (CAL-51-Cas9) using the vector-free (vf) 
CRISPR method and the STAG2 2b crRNA (Supplementary 
Table 2). Seventy-two hours after editing, cells were 
dissociated with trypsin, counted and seeded as single cells 
on 96-well plates. Seven clones were further assessed to 
evaluate the editing status using High Resolution Melting 
Assay (HRMA). Genomic DNA was extracted from each 
clone and from CAL-51-Cas9 cells and a 125-base-pair-
long segment surrounding the STAG2b edited region was 
amplified with specific primers (Supplementary Table 2) 
using MeltDoctor HRM master mix (Applied Biosystems) 
following the manufacturer’s cycling conditions. The 
Applied Biosystems High Resolution Melting Software 
was used to review the melt curves and distinguish between 
homozygous and heterozygous edited clones as compared 
to WT. The homozygous deletion of an eight-base-pair-
long segment was confirmed with Sanger sequencing 
(Supplementary Table 2).
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